Live Breaking News & Updates on Georgia Based Inhibikase Therapeutics

Stay updated with breaking news from Georgia based inhibikase therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IPO Alert: Inhibikase Therapeutics (IKT)


IPO Alert: Inhibikase Therapeutics (IKT)
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol IKT.
Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinson s disease and related disorders.
The company has offered to sell 1.8 million shares of its common stock at a price of $10 each. The underwriters have an option for a period of 45 days to purchase up to an additional 270 thousand shares.
The offering, which is scheduled to close on December 28, is expected to fetch gross proceeds of about $18 million for the company. ....

Bruxelles Capitale , Kostenloser Wertpapierhandel , Paulson Investment Company , Fordham Financial Management Inc , Nasdaq Global Select Market , Georgia Based Inhibikase Therapeutics , Fordham Financial Management , Chronic Myelogenous , Lewy Body , Multiple System Atrophy , Progressive Multifocal , ப்ரூக்ஸெல்ஸ் தலைநகரம் , பால்சன் முதலீடு நிறுவனம் , ஃபார்டம் நிதி மேலாண்மை இன்க் , நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை , ஃபார்டம் நிதி மேலாண்மை , மோசமான உடல் , பல அமைப்பு அட்ரோஃபீ ,